Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) have earned a consensus rating of “Hold” from the seven analysts that are covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $10.13.
CCCC has been the subject of several research analyst reports. Stifel Nicolaus raised their price objective on shares of C4 Therapeutics from $13.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, May 9th. Wells Fargo & Company raised their price objective on shares of C4 Therapeutics from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Thursday, May 9th. Finally, Morgan Stanley lifted their target price on shares of C4 Therapeutics to $8.00 and gave the company an “equal weight” rating in a report on Monday, February 26th.
Check Out Our Latest Stock Analysis on C4 Therapeutics
Hedge Funds Weigh In On C4 Therapeutics
C4 Therapeutics Price Performance
NASDAQ CCCC opened at $4.66 on Monday. The stock has a market capitalization of $320.64 million, a PE ratio of -1.97 and a beta of 3.10. C4 Therapeutics has a 1 year low of $1.06 and a 1 year high of $11.88. The business’s 50-day moving average is $6.35 and its 200 day moving average is $6.37.
C4 Therapeutics (NASDAQ:CCCC – Get Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.41) EPS for the quarter, hitting the consensus estimate of ($0.41). C4 Therapeutics had a negative net margin of 629.24% and a negative return on equity of 52.85%. The business had revenue of $3.04 million during the quarter, compared to analyst estimates of $10.93 million. As a group, equities research analysts anticipate that C4 Therapeutics will post -1.56 earnings per share for the current year.
About C4 Therapeutics
C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.
Featured Articles
- Five stocks we like better than C4 Therapeutics
- How to Use the MarketBeat Dividend Calculator
- MarketBeat Week in Review – 6/3 – 6/7
- Where to Find Earnings Call Transcripts
- Geron Corporation: FDA Approval Fuels Stock Price Surge
- The How and Why of Investing in Gold Stocks
- Intel’s Secret Plan for a Double-Digit Stock Rally Revealed
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.